» Articles » PMID: 32323924

Regulating Cellular Cyclic Adenosine Monophosphate: "Sources," "sinks," and Now, "tunable Valves"

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

A number of hormones and growth factors stimulate target cells via the second messenger pathways, which in turn regulate cellular phenotypes. Cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger that facilitates numerous signal transduction pathways; its production in cells is tightly balanced by ligand-stimulated receptors that activate adenylate cyclases (ACs), that is, "source" and by phosphodiesterases (PDEs) that hydrolyze it, that is, "sinks." Because it regulates various cellular functions, including cell growth and differentiation, gene transcription and protein expression, the cAMP signaling pathway has been exploited for the treatment of numerous human diseases. Reduction in cAMP is achieved by blocking "sources"; however, elevation in cAMP is achieved by either stimulating "source" or blocking "sinks." Here we discuss an alternative paradigm for the regulation of cellular cAMP via GIV/Girdin, the prototypical member of a family of modulators of trimeric GTPases, Guanine nucleotide Exchange Modulators (GEMs). Cells upregulate or downregulate cellular levels of GIV-GEM, which modulates cellular cAMP via spatiotemporal mechanisms distinct from the two most often targeted classes of cAMP modulators, "sources" and "sinks." A network-based compartmental model for the paradigm of GEM-facilitated cAMP signaling has recently revealed that GEMs such as GIV serve much like a "tunable valve" that cells may employ to finetune cellular levels of cAMP. Because dysregulated signaling via GIV and other GEMs has been implicated in multiple disease states, GEMs constitute a hitherto untapped class of targets that could be exploited for modulating aberrant cAMP signaling in disease states. This article is categorized under: Models of Systems Properties and Processes > Mechanistic Models Biological Mechanisms > Cell Signaling.

Citing Articles

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.

Delyon J, Becherirat S, Roger A, Bernard-Cacciarella M, Reger De Moura C, Louveau B Cell Commun Signal. 2024; 22(1):559.

PMID: 39574163 PMC: 11580363. DOI: 10.1186/s12964-024-01941-y.


H NMR Profiling of Honey Bee Brains across Varying Ages and Seasons.

Morfin N, Goodwin P, Guzman-Novoa E, Legge N, Longstaffe J Insects. 2024; 15(8).

PMID: 39194783 PMC: 11354335. DOI: 10.3390/insects15080578.


Electrophysiological Remodeling: Cardiac T-Tubules and ß-Adrenoceptors.

Wright P, Gorelik J, Harding S Cells. 2021; 10(9).

PMID: 34572106 PMC: 8468945. DOI: 10.3390/cells10092456.


GIV/Girdin, a non-receptor modulator for Gαi/s, regulates spatiotemporal signaling during sperm capacitation and is required for male fertility.

Reynoso S, Castillo V, Katkar G, Lopez-Sanchez I, Taheri S, Espinoza C Elife. 2021; 10.

PMID: 34409938 PMC: 8376251. DOI: 10.7554/eLife.69160.


cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease.

Elnagdy M, Barve S, McClain C, Gobejishvili L Biomolecules. 2020; 10(10).

PMID: 33050657 PMC: 7600246. DOI: 10.3390/biom10101433.

References
1.
Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y . Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol. 2013; 32(1):47.e21-8. DOI: 10.1016/j.urolonc.2013.06.017. View

2.
Sigismund S, Avanzato D, Lanzetti L . Emerging functions of the EGFR in cancer. Mol Oncol. 2017; 12(1):3-20. PMC: 5748484. DOI: 10.1002/1878-0261.12155. View

3.
Perez D, Smagley Y, Garcia M, Carter M, Evangelisti A, Matlawska-Wasowska K . Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia. Oncotarget. 2016; 7(23):33960-82. PMC: 5085131. DOI: 10.18632/oncotarget.8986. View

4.
Gooding A, Schiemann W . Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Transl Cancer Res. 2017; 5(Suppl 2):S226-S232. PMC: 5495186. DOI: 10.21037/tcr.2016.08.09. View

5.
Houslay M, Milligan G . Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci. 1997; 22(6):217-24. DOI: 10.1016/s0968-0004(97)01050-5. View